Cargando…

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost

We report long-term results (median follow-up 12 years) of hypofractionated accelerated radiotherapy (HypoAR) in patients treated with breast-conserving surgery. In total, 367 women were treated with HypoAR. Axillary and supraclavicular area (ASA) were treated in patients with involved nodes. In tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Koukourakis, Ioannis M., Panteliadou, Marianthi, Giakzidis, Axiotis G., Nanos, Christos, Abatzoglou, Ioannis, Giatromanolaki, Alexandra, Koukourakis, Michael I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482084/
https://www.ncbi.nlm.nih.gov/pubmed/34590607
http://dx.doi.org/10.3390/curroncol28050300
_version_ 1784576821291909120
author Koukourakis, Ioannis M.
Panteliadou, Marianthi
Giakzidis, Axiotis G.
Nanos, Christos
Abatzoglou, Ioannis
Giatromanolaki, Alexandra
Koukourakis, Michael I.
author_facet Koukourakis, Ioannis M.
Panteliadou, Marianthi
Giakzidis, Axiotis G.
Nanos, Christos
Abatzoglou, Ioannis
Giatromanolaki, Alexandra
Koukourakis, Michael I.
author_sort Koukourakis, Ioannis M.
collection PubMed
description We report long-term results (median follow-up 12 years) of hypofractionated accelerated radiotherapy (HypoAR) in patients treated with breast-conserving surgery. In total, 367 women were treated with HypoAR. Axillary and supraclavicular area (ASA) were treated in patients with involved nodes. In total, 290 patients (scheme A) received 3.5 Gy/day ×10 fractions (breast/ASA) followed by two 4 Gy fractions with electrons to the affected breast quadrant within 16 days. In total, 77 patients (Scheme B) received 2.7 Gy/day for 16 consecutive fractions (breast/ASA) within 22 days, while concurrently, the affected breast quadrant received an electron booster dose of 0.8 Gy for the first 13 fractions. Amifostine was offered to 252/367 patients. Early radiation toxicity was minimal. Regarding late toxicities, symptomatic breast edema was noted in 2.2%, asymptomatic breast fibrosis in 1.9%, and arm lymphedema in 3.7% of patients. Amifostine reduced early radiation dermatitis (p = 0.001). In total, 2.2% of patients developed contralateral breast and 1.6% other carcinomas. Locoregional recurrence (LR) occurred in 3.1% of patients (0% for in situ carcinomas). Positive margins after surgery, extracapsular node invasion, and HER2-enriched/triple-negative tumors were linked with significantly worse LR-free survival. The involvement of more than three nodes and luminal type other than A were independent prognostic variables of metastasis and death events. HypoAR delivering a biological dose of 50–52 Gy to the breast/ASA is a safe and effective therapy for patients treated with conservative surgery. The risk of carcinogenesis is low. Positive surgical margins, extracapsular node invasion, and HER2-enriched/triple-negative phenotypes appear as a cluster of features linked with a higher risk for locoregional relapse.
format Online
Article
Text
id pubmed-8482084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84820842021-10-01 Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost Koukourakis, Ioannis M. Panteliadou, Marianthi Giakzidis, Axiotis G. Nanos, Christos Abatzoglou, Ioannis Giatromanolaki, Alexandra Koukourakis, Michael I. Curr Oncol Article We report long-term results (median follow-up 12 years) of hypofractionated accelerated radiotherapy (HypoAR) in patients treated with breast-conserving surgery. In total, 367 women were treated with HypoAR. Axillary and supraclavicular area (ASA) were treated in patients with involved nodes. In total, 290 patients (scheme A) received 3.5 Gy/day ×10 fractions (breast/ASA) followed by two 4 Gy fractions with electrons to the affected breast quadrant within 16 days. In total, 77 patients (Scheme B) received 2.7 Gy/day for 16 consecutive fractions (breast/ASA) within 22 days, while concurrently, the affected breast quadrant received an electron booster dose of 0.8 Gy for the first 13 fractions. Amifostine was offered to 252/367 patients. Early radiation toxicity was minimal. Regarding late toxicities, symptomatic breast edema was noted in 2.2%, asymptomatic breast fibrosis in 1.9%, and arm lymphedema in 3.7% of patients. Amifostine reduced early radiation dermatitis (p = 0.001). In total, 2.2% of patients developed contralateral breast and 1.6% other carcinomas. Locoregional recurrence (LR) occurred in 3.1% of patients (0% for in situ carcinomas). Positive margins after surgery, extracapsular node invasion, and HER2-enriched/triple-negative tumors were linked with significantly worse LR-free survival. The involvement of more than three nodes and luminal type other than A were independent prognostic variables of metastasis and death events. HypoAR delivering a biological dose of 50–52 Gy to the breast/ASA is a safe and effective therapy for patients treated with conservative surgery. The risk of carcinogenesis is low. Positive surgical margins, extracapsular node invasion, and HER2-enriched/triple-negative phenotypes appear as a cluster of features linked with a higher risk for locoregional relapse. MDPI 2021-09-07 /pmc/articles/PMC8482084/ /pubmed/34590607 http://dx.doi.org/10.3390/curroncol28050300 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Koukourakis, Ioannis M.
Panteliadou, Marianthi
Giakzidis, Axiotis G.
Nanos, Christos
Abatzoglou, Ioannis
Giatromanolaki, Alexandra
Koukourakis, Michael I.
Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title_full Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title_fullStr Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title_full_unstemmed Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title_short Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
title_sort long-term results of postoperative hypofractionated accelerated breast and lymph node radiotherapy (hypoar) with hypofractionated boost
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482084/
https://www.ncbi.nlm.nih.gov/pubmed/34590607
http://dx.doi.org/10.3390/curroncol28050300
work_keys_str_mv AT koukourakisioannism longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT panteliadoumarianthi longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT giakzidisaxiotisg longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT nanoschristos longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT abatzoglouioannis longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT giatromanolakialexandra longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost
AT koukourakismichaeli longtermresultsofpostoperativehypofractionatedacceleratedbreastandlymphnoderadiotherapyhypoarwithhypofractionatedboost